Effect of Addition of Medicinal Cannabis Treatment To Conventional Treatment in Diabetic Neuropathy Patients

Background: Diabetic neuropathy is unfortunately the most common complication associated with a common malady increasing in prevalence by 5% a year. None of the disease-modifying drugs that have been designed to target multiple metabolic pathways has proven effective. Thus the treatement currently is mostly symptomatic. The current study assessed the ability of cannabis added to maximal conventional therapy to ameliorate diabetic neuropathy symptoms.

Methods: At screening, patients were assessed for possibility of being treated by receiving cannabis therapy (CT, smoking, 20 grams per month) provided that they have completed a period of at least 12 months of optimal conventional treatment including at least one narcotic agent and at least one of following analgesic treatments: tricyclic antidepressants (amitriptyline and nortriptyline), anticonvulsants (gabapentin and pregabalin), and serotonin-norepinephrine reuptake inhibitors (SNRIs) (duloxetine and venlafaxine). Patients suitable for CT, were treated for at least 3 months more by alpha lipoic acid 600mg, vitamin B complex, duloxetine 30 mg and tramadol 100 mg up to thrice a day. If after 3 months of treatment, the patients were still painful (BPI pain severity higher than 7) cannabis therapy was begun. Patients were followed up every 6 months for up to one year. The following patient reported outcome scores (PRO`s) were collected: VAS pain intensity, VAS pain severity, BPI pain severity, BPI pain interference and SF12.

Results: 89 patients were screened. 15 of them improved after 3 months of maximal conventional therapy, and thus did not meet the inclusion criteria of minimal pain seveity. 74 patients begun cannabis therapy and results are available after 6 months for 73 of them, and 70 patients were followed up to 12 months. 4/74 patients stopped CT (1/74 due to ileus, 3/74 due to pain resolution). BPI pain severity decreased from 9.4±0.8 to 4.3±1.7 at six months, while pain interference decreased from 8.6±1.1 to 3.7±1.6. SF12v2 Physical compounded score (PCS) changed from 34±8 to 46±8 at 6M.